The House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) and Subcommittee on Health Chair Brett Guthrie (R-KY) announced a hearing titled “Check Up: Examining FDA Regulation of Drugs, Biologics, and Devices.” The Chairs stated that America is a leader in developing cutting-edge biomedical innovation, with countries around the globe looking to the FDA for guidance on safe and effective treatments and medical devices.
As part of their ongoing efforts to ensure the safety and efficacy of drugs, biologics, and devices, the Subcommittee on Health will hold a hearing to examine the regulation of these products by the Food and Drug Administration (FDA). The hearing is scheduled for Wednesday, May 22, 2024, at 10:30 AM ET at 2322 Rayburn House Office Building.
Witnesses at the hearing will include Dr. Patrizia Cavazzoni, Director of the Center for Drug Evaluation and Research (CDER) at the FDA, Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) at the FDA, and Dr. Jeffrey Shuren, Director of the Center for Devices and Radiological Health (CDRH) at the FDA. These experts will provide insights into the current state of drug regulation in their respective fields.
The hearing will be open to the public and press, offering an opportunity to observe firsthand how these important regulatory agencies operate in practice. For those who cannot attend in person, it will also be live streamed online at https://energycommerce.house.gov/.
For questions about this event or related matters involving health care policy in Congress
